TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17433955

Group type: EXPERIMENTAL
Intervention: 8‐mm catheter (8MC)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: OIC‐1 (open irrigation catheter with higher peak power 50 W)
Number of subjects: 180

Group type: COMPARATOR
Intervention: OIC‐2 (open irrigation catheter with lower peak power 35 W)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: OIC‐1
Number of subjects: 180

Group type: COMPARATOR
Intervention: OIC‐2
Number of subjects: 180

Group type: COMPARATOR
Intervention: 8MC
Number of subjects: 180
Study: 16115731

Group type: EXPERIMENTAL
Intervention: LRRK 2 G 2019 S and I 2020 T mutations evaluation in PD patients
Number of subjects: 174

Group type: COMPARATOR
Intervention: LRRK 2 G 2019 S and I 2020 T mutations evaluation in healthy controls
Number of subjects: 174
Study: 12106929

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion at increasing doses in the infarct-related artery (IRA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh) infusion in the IRA after one year
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (patients with coronary atherosclerosis)
Number of subjects: 16
Study: 10442370

Group type: EXPERIMENTAL
Intervention: UFT plus oral calcium folinate combined with epirubicin and cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous-infusion 5-fluorouracil (5-FU)
Number of subjects: 0
Study: 7926495

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 366
Study: 2555105

Group type: EXPERIMENTAL
Intervention: Operative surgery
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Operative surgery supplemented with physical training
Number of subjects: 38

Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 38
Study: 50828

Group type: EXPERIMENTAL
Intervention: Reinforcement contingency management system
Number of subjects: 10

Group type: COMPARATOR
Intervention: Noncontingent services (Control)
Number of subjects: 10
Study: 31562875

Group type: EXPERIMENTAL
Intervention: Sustained stretch and paraffin
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sustained stretch only
Number of subjects: 23
Study: 29779399

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injection
Number of subjects: 28

Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 28
Study: 28139240

Group type: EXPERIMENTAL
Intervention: Frozen embryo transfer
Number of subjects: 179

Group type: COMPARATOR
Intervention: Fresh embryo transfer
Number of subjects: 179
Study: 25647628

Group type: EXPERIMENTAL
Intervention: Sunitinib administered at 1 p.m.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sunitinib administered at 6 p.m.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sunitinib administered at 8 a.m.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sunitinib administered at 4 a.m. and 4 p.m.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sunitinib administered at different times (8 a.m., 1 p.m., 6 p.m.).
Number of subjects: 12
Study: 24369195

Group type: EXPERIMENTAL
Intervention: Fosaprepitant (150 mg IV on day 1)
Number of subjects: 372

Group type: COMPARATOR
Intervention: Aprepitant (125 mg on day 1, 80 mg on days 2 and 3)
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Number of subjects: 372

Group type: COMPARATOR
Intervention: Aprepitant
Number of subjects: 372

Group type: EXPERIMENTAL
Intervention: Fosaprepitant and Aprepitant
Number of subjects: 372
Study: 21339093

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Pethidine
Number of subjects: 35
Study: 18989715

Group type: EXPERIMENTAL
Intervention: Self-adjustment of mandibular advancement splint (MAS) for 6 weeks (n = 16)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Objective adjustment of MAS (fixed position for 3 weeks, then PSG feedback for 3 weeks, n = 12)
Number of subjects: 28
Study: 17052970

Group type: EXPERIMENTAL
Intervention: Active extract group (botanical extract-based weight loss formula)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 105
Study: 12765889

Group type: EXPERIMENTAL
Intervention: Intrathecal (i.t.) clonidine 150 microg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intrathecal (i.t.) clonidine 50 microg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intrathecal (i.t.) bupivacaine with clonidine (150 microg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Intramuscular (i.m.) clonidine 150 microg
Number of subjects: 24
Study: 10694109

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM) 20 g x d(‐1) x 5 d
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 30
Study: 10169635

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8238193

Group type: COMPARATOR
Intervention: Transdermal estradiol (0.05 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Three estradiol implants
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: One estradiol implant
Number of subjects: 36
Study: 3567018

Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg) in young volunteers
Number of subjects: 11

Group type: COMPARATOR
Intervention: Carbamazepine (400 mg) in elderly volunteers
Number of subjects: 11
Study: 29856114

Group type: EXPERIMENTAL
Intervention: Insulin dosing for both protein and carbohydrate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Carbohydrate alone
Number of subjects: 16
Study: 27012370

Group type: EXPERIMENTAL
Intervention: SLIPA
Number of subjects: 100

Group type: COMPARATOR
Intervention: Laryngeal Mask Airway‐Unique
Number of subjects: 100
Study: 24752448

Group type: EXPERIMENTAL
Intervention: Sequential therapy (BCG and electromotive mitomycin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sequential therapy vs BCG alone
Number of subjects: 0
Study: 22585285

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg under fasting conditions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg under high-fat meal (HFM) conditions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tolvaptan 30 mg under Japanese standard meal conditions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (fasted state)
Number of subjects: 49
Study: 20876412

Group type: EXPERIMENTAL
Intervention: Pregabalin (150 to 600 mg/d over 6 weeks)
Number of subjects: 324

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 324
Study: 19027496

Group type: EXPERIMENTAL
Intervention: Transfer for primary angioplasty
Number of subjects: 5741

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 5741
Study: 15764724

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone (3,000 microg/hour) administered through a metered‐dose inhaler and spacer at 10‐minute intervals for 3 hours
Number of subjects: 106

Group type: COMPARATOR
Intervention: Intravenous hydrocortisone (500 mg)
Number of subjects: 106
Study: 12426672

Group type: EXPERIMENTAL
Intervention: 16 Gy electron irradiation
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: 12-14.25 Gy HDR BT
Number of subjects: 207

Group type: COMPARATOR
Intervention: No further radiotherapy (control)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Boost (either electron or HDR BT)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: HDR BT
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Electron boost
Number of subjects: 207
Study: 10487192

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP), 2,400 mg/day
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ), mean 731 mg/day
Number of subjects: 35

Group type: COMPARATOR
Intervention: Nondrug average
Number of subjects: 35
Study: 8754957

Group type: EXPERIMENTAL
Intervention: Asthmatic patients at high altitude (2nd night)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy controls at high altitude (2nd night)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Asthmatic patients at high altitude (7th night)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Healthy controls at high altitude (7th night)
Number of subjects: 8
Study: 1912554

Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin (rhEPO) at a dose of 1,200 to 1,600 U/kg intravenously (IV) twice weekly
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 6125180

Group type: EXPERIMENTAL
Intervention: Pindolol 0.4 mg i.v. (n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Metoprolol 5 mg i.v. (n = 11)
Number of subjects: 21
Study: 31313807

Group type: EXPERIMENTAL
Intervention: Written plus video instructions (video group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Written preoperative instructions (control)
Number of subjects: 120
Study: 30864618

Group type: EXPERIMENTAL
Intervention: Manual chest compression (MCC) with PEEP-ZEEP maneuver
Number of subjects: 10

Group type: COMPARATOR
Intervention: PEEP-ZEEP maneuver without MCC
Number of subjects: 10
Study: 28724171

Group type: EXPERIMENTAL
Intervention: Beta-glucan, inositol and digestive enzymes (one tablet after lunch and dinner for four weeks)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional treatment (systemic and topical mesalamine)
Number of subjects: 43
Study: 27180954

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 500 mg t.i.d.
Number of subjects: 232

Group type: COMPARATOR
Intervention: Methylcobalamin (MC) 0.5 mg t.i.d.
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Both ALC and MC
Number of subjects: 232
Study: 24618331

Group type: EXPERIMENTAL
Intervention: 3D CEUS
Number of subjects: 23

Group type: COMPARATOR
Intervention: 2D CEUS
Number of subjects: 23

Group type: COMPARATOR
Intervention: CTA
Number of subjects: 23
Study: 21278624

Group type: EXPERIMENTAL
Intervention: HIV-1 infected women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HSV-2 infected women
Number of subjects: 0
Study: 19720444

Group type: EXPERIMENTAL
Intervention: AEDs with open lid mechanism
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AEDs with pull handle mechanism
Number of subjects: 120

Group type: COMPARATOR
Intervention: AEDs with push button mechanism
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AEDs with detailed voice instruction for pad placement
Number of subjects: 120

Group type: COMPARATOR
Intervention: AEDs without detailed voice instruction for pad placement
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: AEDs with step-by-step CPR instruction
Number of subjects: 120

Group type: COMPARATOR
Intervention: AEDs that only prompted to start CPR
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: All AED models
Number of subjects: 120
Study: 17543680

Group type: EXPERIMENTAL
Intervention: Carotid Angioplasty with Stent placement (CAS)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 24
Study: 15120657

Group type: EXPERIMENTAL
Intervention: Competency decomposition method for ontology specification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard method for developing domain ontologies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized controlled trials (RCTs)
Number of subjects: 0
Study: 11347658

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (n = 13; 32 lesions)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Professional tooth-cleaning (n = 18; 30 lesions)
Number of subjects: 31
Study: 9154674

Group type: EXPERIMENTAL
Intervention: Thymostimulin (1 mg/kg day for the 1st week followed by once a week for 6 months)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard treatment for COPD (Control group)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Thymostimulin
Number of subjects: 78
Study: 7696830

Group type: EXPERIMENTAL
Intervention: Transdermal HRT (continuous 17 beta‐oestradiol 0.05 mg/day, with 0.25 mg/day of norethisterone acetate for 14 days of each 28‐day cycle)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Oral HRT (continuous conjugated equine oestrogens 0.625 mg/day, with 0.15 mg/day dl‐norgestrel for 12 days of each 28‐day cycle)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Untreated group (30 matched untreated women)
Number of subjects: 66
Study: 3301985

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with enterosoluble capsules (cumulated dose of 280 times 10(6) biologic units of birch pollen extract)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral immunotherapy with enterosoluble capsules
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 39
Study: 28843974

Group type: EXPERIMENTAL
Intervention: Non-violent video game (FIFA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Violent video game (Call of Duty)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Non-violent television (control group)
Number of subjects: 72
Study: 26836910

Group type: EXPERIMENTAL
Intervention: Older age group (≥ 65 years)
Number of subjects: 2627
Study: 25492496

Group type: EXPERIMENTAL
Intervention: Injury Prevention Briefing (IPB) supplemented by initial training and regular facilitation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Injury Prevention Briefing (IPB) sent by post with no facilitation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Injury Prevention Briefing (IPB)
Number of subjects: 24
Study: 22770948

Group type: EXPERIMENTAL
Intervention: Positive Choices program (PC)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 449
Study: 20493183

Group type: EXPERIMENTAL
Intervention: Mud bath treatments combined with hydropinotherapy (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mud bath treatments without hydropinotherapy (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No spa therapies (Group C)
Number of subjects: 0
Study: 18076257

Group type: EXPERIMENTAL
Intervention: Complex training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Plyometric-only training
Number of subjects: 45

Group type: COMPARATOR
Intervention: Heavy resistance training
Number of subjects: 45
Study: 16115985

Group type: EXPERIMENTAL
Intervention: Visible monitoring of cerebral oxygen saturation (rSO(2)) maintained at > or =75% of preinduction values (n = 56)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Blinded monitoring with routine anesthesia management (n = 66)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Visible monitoring of rSO(2)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Blinded monitoring with routine anesthesia management
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group with intraoperative cerebral desaturation
Number of subjects: 122
Study: 12324722

Group type: EXPERIMENTAL
Intervention: Reduction pneumoplasty
Number of subjects: 60

Group type: COMPARATOR
Intervention: Respiratory rehabilitation
Number of subjects: 60
Study: 10425301

Group type: EXPERIMENTAL
Intervention: Dose-intensive chemotherapy (DI-PVM) consisting of 3 cycles of cisplatin: 80 mg/m2 (day 1), vindesine: 3 mg/m2 (days 1 and 8), and mitomycin C: 8 mg/m2 (day 1) in 3-week intervals with concurrent G-CSF.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard chemotherapy (PVM) consisting of 2 cycles of the same chemotherapy in 4-week intervals.
Number of subjects: 100
Study: 7588144

Group type: EXPERIMENTAL
Intervention: Rebound tenderness
Number of subjects: 123

Group type: COMPARATOR
Intervention: Other physical signs (guarding, rigidity, Rovsing's sign)
Number of subjects: 123
Study: 2138974

Group type: EXPERIMENTAL
Intervention: Gestodene (GES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both GES and LNG
Number of subjects: 0
Study: 111275

Group type: EXPERIMENTAL
Intervention: Clorgyline (selective MAO‐A inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pargyline (selective MAO‐B inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clorgyline and Pargyline
Number of subjects: 0
Study: 30615024

Group type: EXPERIMENTAL
Intervention: CAPABLE intervention (10 home visits over 5 months by occupational therapists, registered nurses, and home modifiers)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: CAPABLE intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (10 social home visits by a research assistant)
Number of subjects: 300
Study: 27863460

Group type: EXPERIMENTAL
Intervention: Integrated Olympic education programme
Number of subjects: 841

Group type: COMPARATOR
Intervention: Control group (no Olympic education programme)
Number of subjects: 841
Study: 26298619

Group type: EXPERIMENTAL
Intervention: 3F-PCC 25 IU/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3F-PCC 50 IU/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Edoxaban 180 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 3F-PCC infusion
Number of subjects: 24
Study: 23365005

Group type: EXPERIMENTAL
Intervention: Regular and systematic exercise regimens
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise intervention)
Number of subjects: 40
Study: 22011892

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation (1.5 W, 100 mJ, 15 Hz)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no additional treatment, filled with vertically condensed gutta-percha)
Number of subjects: 34
Study: 19228209

Group type: EXPERIMENTAL
Intervention: Immediate post‐space preparation with Resilon/Epiphany
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Delayed post‐space preparation (5 days later) with Resilon/Epiphany
Number of subjects: 80

Group type: COMPARATOR
Intervention: Positive control (Resilon master cones without sealer)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Negative control (not obturated, sealed with fingernail polish)
Number of subjects: 80
Study: 15978846

Group type: EXPERIMENTAL
Intervention: 25 mg of sultopride
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 50 mg of fluvoxamine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 12553591

Group type: EXPERIMENTAL
Intervention: Intravenous synthetic human secretin (2 IU/kg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intravenous saline placebo
Number of subjects: 42
Study: 10609208

Group type: EXPERIMENTAL
Intervention: Healon GV (sodium hyaluronate 1.4%)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Viscoat (sodium chondroitin sulfate 4.0%‐sodium hyaluronate 3.0%)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Viscoat
Number of subjects: 140
Study: 7503516

Group type: EXPERIMENTAL
Intervention: Syringe-assisted liposuction using the superwet or tumescent technique
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Syringe-assisted liposuction
Number of subjects: 22
Study: 2248121

Group type: EXPERIMENTAL
Intervention: Behavioral intervention and cognitive intervention focused on changing maladaptive self-statements
Number of subjects: 63

Group type: COMPARATOR
Intervention: Behavioral intervention
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Behavioral intervention and cognitive intervention
Number of subjects: 63
Study: 7027279

Group type: EXPERIMENTAL
Intervention: Trazodone (TZ)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Amitriptyline (AMT)
Number of subjects: 43
Study: 31703648

Group type: EXPERIMENTAL
Intervention: Per‐oral carbohydrate load (preOp™) 18 and 2‐4 h before surgery (n=26)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard pre‐operative fasting with free consumption of tap water (n=35)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Per‐oral carbohydrate load (preOp™)
Number of subjects: 61
Study: 28322474

Group type: EXPERIMENTAL
Intervention: Ixekizumab (80 mg subcutaneous every 2 or 4 weeks after a 160 mg starting dose)
Number of subjects: 3866

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3866

Group type: COMPARATOR
Intervention: Etanercept (50 mg biweekly)
Number of subjects: 3866
Study: 25377269

Group type: EXPERIMENTAL
Intervention: Ghrelin administration (3 μg/kg, twice a day)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ghrelin administration (0.5 μg/kg/h continuous infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ghrelin administration (both regimens)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no ghrelin administration)
Number of subjects: 20
Study: 24088225

Group type: EXPERIMENTAL
Intervention: Lovastatin (200 mg for 4 days)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy controls (HC)
Number of subjects: 11
Study: 21107813

Group type: EXPERIMENTAL
Intervention: Alpha-blocker monotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Extracorporeal magnetic innervations (ExMI) monotherapy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination therapy (alpha-blocker + ExMI)
Number of subjects: 60
Study: 19594851

Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac (31.5 mg) three times daily for up to 5 days
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Intranasal ketorolac
Number of subjects: 300
Study: 17379850

Group type: EXPERIMENTAL
Intervention: Combined EBUS and ENB
Number of subjects: 120

Group type: COMPARATOR
Intervention: EBUS only
Number of subjects: 120

Group type: COMPARATOR
Intervention: ENB only
Number of subjects: 120
Study: 16283538

Group type: EXPERIMENTAL
Intervention: Infusion rates of the drug (individualized to achieve the same target concentration)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Markov model for side-effect analysis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Model without Markov elements
Number of subjects: 12
Study: 12076871

Group type: EXPERIMENTAL
Intervention: Daily high dose interferon (IFN) for 6 weeks followed by standard therapy of 3 million units three times a week in combination with ribavirin for 42 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Twice daily high dose interferon (IFN) for 6 weeks followed by standard therapy of 3 million units three times a week in combination with ribavirin for 42 weeks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Induction IFN therapy followed by combination IFN plus ribavirin
Number of subjects: 28